Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis

[1]  P. Wesseling,et al.  Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases , 2022, Cancers.

[2]  L. Norton,et al.  Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases , 2022, NPJ breast cancer.

[3]  Youngju Kim,et al.  Senolytic Therapy for Cerebral Ischemia-Reperfusion Injury , 2021, International journal of molecular sciences.

[4]  T. Kiss,et al.  Treatment with the BCL-2/BCL-xL inhibitor senolytic drug ABT263/Navitoclax improves functional hyperemia in aged mice , 2021, GeroScience.

[5]  P. D. de Keizer,et al.  Residual Disease in Glioma Recurrence: A Dangerous Liaison with Senescence , 2021, Cancers.

[6]  Kenneth G. C. Smith,et al.  A CD8+ NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis , 2021, Nature Communications.

[7]  Kelvin K. W. Chan,et al.  The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. , 2020, Neuro-oncology.

[8]  L. Zitvogel,et al.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors , 2020, Nature Reviews Clinical Oncology.

[9]  N. Lin,et al.  A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer , 2020, Clinical Cancer Research.

[10]  J. Bosch-Barrera,et al.  Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. , 2020, Cancer treatment reviews.

[11]  M. Demaria,et al.  Senescent Cells in Cancer Therapy: Friends or Foes? , 2020, Trends in cancer.

[12]  S. Loi,et al.  KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. , 2020 .

[13]  C. Brennan,et al.  Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells , 2020, Cell.

[14]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[15]  Amanda R. Kulick,et al.  Senolytic CAR T cells reverse senescence-associated pathologies , 2020, Nature.

[16]  Amanda R. Kulick,et al.  Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer , 2020, Cell.

[17]  N. Ibrahim,et al.  ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases , 2020, Clinical Cancer Research.

[18]  R. Greil,et al.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.

[19]  Norikazu Masuda,et al.  Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples , 2019, Scientific Reports.

[20]  R. Bernards,et al.  Inducing and exploiting vulnerabilities for the treatment of liver cancer , 2019, Nature.

[21]  S. Stewart,et al.  Unmasking senescence: context-dependent effects of SASP in cancer , 2019, Nature Reviews Cancer.

[22]  L. Moretta,et al.  PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells , 2019, Front. Immunol..

[23]  H. Horlings,et al.  Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial , 2019, Nature Medicine.

[24]  L. Sevenich.  Turning “Cold” Into “Hot” Tumors—Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers , 2019, Front. Oncol..

[25]  S. Macip,et al.  Radiotherapy-Induced Senescence and its Effects on Responses to Treatment. , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[26]  I. Pastan,et al.  Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors , 2019, PloS one.

[27]  John T. Poirier,et al.  NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination , 2018, Science.

[28]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[29]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[30]  M. McBurney,et al.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade , 2018, The Journal of clinical investigation.

[31]  M. Djamgoz,et al.  Immuno-Oncology: Emerging Targets and Combination Therapies , 2018, Front. Oncol..

[32]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[33]  H. Clevers,et al.  Organoids in cancer research , 2018, Nature Reviews Cancer.

[34]  P. Kumthekar,et al.  Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma. , 2018, Future oncology.

[35]  A. Letai,et al.  Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis , 2017, Science Translational Medicine.

[36]  O. Dreesen,et al.  Loss of lamin B1 is a biomarker to quantify cellular senescence in photoaged skin , 2017, Scientific Reports.

[37]  K. Kaestner,et al.  Cytoplasmic chromatin triggers inflammation in senescence and cancer , 2017, Nature.

[38]  A. Santoni,et al.  Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance , 2017, Front. Immunol..

[39]  L. Zender,et al.  Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence , 2017, Nature Cell Biology.

[40]  Emily A Foley,et al.  Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents , 2017, Cell reports.

[41]  S. Bates,et al.  Current challenges in the management of breast cancer brain metastases. , 2017, Seminars in oncology.

[42]  Wiggert A. van Cappellen,et al.  Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging , 2017, Cell.

[43]  D. Quail,et al.  The Microenvironmental Landscape of Brain Tumors. , 2017, Cancer cell.

[44]  Dihua Yu,et al.  Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis. , 2017, Journal of visualized experiments : JoVE.

[45]  B. Engelhardt,et al.  The movers and shapers in immune privilege of the CNS , 2017, Nature Immunology.

[46]  D. Olive,et al.  PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma , 2016, Oncotarget.

[47]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[48]  H. Wurdak,et al.  Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases , 2016, Oncotarget.

[49]  S. Loi,et al.  Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis , 2016, Breast Cancer Research.

[50]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[51]  A. van Oudenaarden,et al.  Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity , 2016, Cell reports.

[52]  N. Sharpless,et al.  Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice , 2015, Nature Medicine.

[53]  K. D. de Visser,et al.  Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy , 2015, Front. Immunol..

[54]  Jonathan Kipnis,et al.  Revisiting the Mechanisms of CNS Immune Privilege. , 2015, Trends in immunology.

[55]  A. Korman,et al.  FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. , 2015, Cancer cell.

[56]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[57]  P. Pandolfi,et al.  Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. , 2014, Cell reports.

[58]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[59]  J. van Rheenen,et al.  In vivo imaging and histochemistry are combined in the cryosection labelling and intravital microscopy technique , 2013, Nature Communications.

[60]  Soyoung Lee,et al.  Synthetic lethal metabolic targeting of cellular senescence in cancer therapy , 2013, Nature.

[61]  A. El‐Naggar,et al.  p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. , 2012, Cancer cell.

[62]  J. Campisi,et al.  Lamin B1 loss is a senescence-associated biomarker , 2012, Molecular biology of the cell.

[63]  P. D. de Jong,et al.  Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons , 2011, Molecular biology of the cell.

[64]  T. Luedde,et al.  Senescence surveillance of pre-malignant hepatocytes limits liver cancer development , 2011, Nature.

[65]  David F Jarrard,et al.  Therapy-induced senescence in cancer. , 2010, Journal of the National Cancer Institute.

[66]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[67]  Shan Zhu,et al.  BMP4-Smad Signaling Pathway Mediates Adriamycin-induced Premature Senescence in Lung Cancer Cells* , 2009, Journal of Biological Chemistry.

[68]  P. Barker,et al.  Can Proton MR Spectroscopic and Perfusion Imaging Differentiate Between Neoplastic and Nonneoplastic Brain Lesions in Adults? , 2008, American Journal of Neuroradiology.

[69]  Yuhui Yang,et al.  Quantification of pegylated liposomal doxorubicin and doxorubicinol in rat plasma by liquid chromatography/electrospray tandem mass spectroscopy: Application to preclinical pharmacokinetic studies. , 2008, Talanta.

[70]  Donald Kennedy,et al.  Breakthrough of the Year , 2007, Science.

[71]  Jayanta Debnath,et al.  Modelling glandular epithelial cancers in three-dimensional cultures , 2005, Nature Reviews Cancer.

[72]  F. Martin,et al.  Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. , 2004, Seminars in oncology.

[73]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  V. L. Doyle,et al.  Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy , 2003, Magnetic resonance in medicine.

[75]  Sophie Lelièvre,et al.  beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. , 2002, Cancer cell.

[76]  Soyoung Lee,et al.  A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy , 2002, Cell.

[77]  Piero Musiani,et al.  Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.

[78]  B. Hunt,et al.  Endothelial cell activation , 1998, BMJ.

[79]  B. Miller.  A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline , 1991, NMR in biomedicine.

[80]  B. Caillou,et al.  CD44 contributes to T cell activation. , 1989, Journal of immunology.

[81]  OUP accepted manuscript , 2022, The Oncologist.

[82]  Naveid A Ali,et al.  Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. , 2015, Cancer discovery.

[83]  M. Barberi-Heyob,et al.  Preclinical Studies of Pegylated- and Non-Pegylated Liposomal Forms of Doxorubicin as Radiosensitizer on Orthotopic High-Grade Glioma Xenografts , 2014, Pharmaceutical Research.

[84]  A. Khandji,et al.  Review of imaging techniques in the diagnosis and management of brain metastases. , 2011, Neurosurgery clinics of North America.